IRIS
PISTELLI, MIRCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.021
EU - Europa 376
AS - Asia 129
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 1.558
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.021
IT - Italia 86
SE - Svezia 69
IE - Irlanda 67
UA - Ucraina 57
CN - Cina 56
SG - Singapore 43
DE - Germania 35
CI - Costa d'Avorio 22
FR - Francia 17
GB - Regno Unito 16
TR - Turchia 16
DK - Danimarca 14
FI - Finlandia 10
KR - Corea 8
MA - Marocco 7
BE - Belgio 4
IN - India 4
EU - Europa 2
JP - Giappone 2
AU - Australia 1
RO - Romania 1
Totale 1.558
Salva come PNG Salva come JPEG
Città #
Chandler 170
Jacksonville 89
Ashburn 83
Fairfield 80
Dublin 66
Boardman 55
Des Moines 54
Houston 41
New York 40
Woodbridge 40
Seattle 38
Wilmington 38
Cambridge 27
Abidjan 22
Lawrence 22
Princeton 22
Ann Arbor 21
San Mateo 20
Centro 15
Beijing 12
San Diego 12
Singapore 12
Turin 9
Washington 9
Porto 8
Cagliari 6
Dallas 6
Cantu 5
Chiaravalle 5
Falls Church 5
Brussels 4
Guangzhou 4
Prescot 4
Pune 4
Rome 4
Helsinki 3
Kilburn 3
London 3
Wuhan 3
Yiwu 3
Caserta 2
Chengdu 2
Hangzhou 2
Marche 2
Osimo 2
Qingdao 2
Recanati 2
Redmond 2
Redwood City 2
Southwark 2
Ancona 1
Arqua Petrarca 1
Avant-lès-marcilly 1
Brisbane 1
Cedar Knolls 1
Civitanova Marche 1
Clifton 1
Dalian 1
Dangan 1
Duncan 1
Handan 1
Hounslow 1
Jinhua 1
Los Angeles 1
Mestre 1
Norwalk 1
Philadelphia 1
Phoenix 1
San Costanzo 1
Scafati 1
Shanghai 1
Shaoxing 1
Shenzhen 1
Sioux Falls 1
Suzhou 1
Verona 1
Wuxi 1
Xi'an 1
Totale 1.115
Salva come PNG Salva come JPEG
Nome #
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 105
Role of DCE-MR in predicting breast cancer subtypes. 101
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 95
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 92
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 88
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 86
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 85
Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit? 76
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 76
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report 75
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 73
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 71
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 66
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors 64
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 62
Adjuvant Systemic Therapy in DCIS 62
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 58
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 57
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 56
Espressione di p-mTOR e del recettore degli androgeni nei tumori mammari triplo negativi: significato clinico e potenziali prospettive terapeutiche 50
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 48
A Mixed-apprOach program To help women wIth breast cancer stay actiVE (MOTIVE program): A pilot-controlled study 45
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 14
Totale 1.605
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.142
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.142
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020106 0 0 0 0 15 0 10 4 11 14 15 37
2020/2021355 30 34 64 1 29 26 22 28 32 39 33 17
2021/2022184 12 28 4 1 2 29 11 9 17 22 17 32
2022/2023455 31 58 30 49 27 99 0 15 97 2 24 23
2023/2024242 46 3 16 17 33 70 4 16 0 3 0 34
2024/2025135 65 45 11 9 5 0 0 0 0 0 0 0
Totale 1.605